Anzeige
Mehr »
Mittwoch, 11.03.2026 - Börsentäglich über 12.000 News
Das Triple-Discovery-Setup, das der Markt noch nicht begriffen hat!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DiUBS reiterates Buy rating on Darden stock ahead of earnings
DiNeedham reiterates Medtronic stock rating on Scientia deal
DiUBS reiterates Neutral rating on Casey's General Stores stock
DiUBS cuts National Beverage stock price target on cost pressures
DiBofA reiterates Buy on IBM stock, cites agentic AI positioning
DiElanco Animal Health stock reaffirmed at Buy by UBS on innovation momentum
DiUBS raises Academy Sports stock price target to $60 on margin outlook
DiUBS reiterates Norwegian Cruise Line stock rating after tech update
DiStifel reiterates Ondas Holdings stock rating on revenue beat
DiStifel reiterates Vertex stock rating on kidney drug trial data
DiCosan Q4 2025 slides: debt slashed 46% amid mixed operating results
DiCasey's Q3 2026 slides reveal aggressive growth plan amid mixed results
DiCustom Truck Q4 2025 slides: record results mask revenue miss concerns
DiUNFI Q2 FY26 slides: profitability surges amid strategic revenue reset
DiCantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook
DiStifel raises Cullinan Oncology stock price target on autoimmune progress
DiStifel cuts Vail Resorts stock price target on weak snow conditions
DiCantor Fitzgerald reiterates Septerna stock rating on platform value
DiTruist cuts Vail Resorts stock price target on earnings miss
DiStifel reiterates DraftKings stock Buy rating on super app strategy
DiTruist cuts Accenture stock price target on ecosystem concerns
DiTruist cuts Korn/Ferry stock price target on industry multiples
DiMorgan Stanley lowers Yeti stock price target to $47 on tariff concerns
DiCantor Fitzgerald reiterates Overweight on LifeMD stock, $15 target
DiABM Q1 2026 slides: revenue beats offset by margin pressure